1 Antibiotic Prevention of Acute Exacerbations of COPD Dr Farhad Abbasi Infectious Diseases Specialist.

Slides:



Advertisements
Similar presentations
Antimicrobial Prescribing in the Management of COPD
Advertisements

Chest Infections Lawrence Pike.
Chronic Disease and Co-morbidity with Hearing Loss
Treatment of infectious diseases. Drugs used in the treatment of bacterial diseases can be grouped into categories based on their modes of action: 1.
Infection in COPD Pulmonology Subspeciality Rounds (12/11/2008)Dr.Krock Dr.Vysetti Dr.Vysetti.
Diuretic Strategies in Patients with Acute Decompensated Heart Failure Diuretic Optimization Strategies Evaluation (DOSE) trial.
Training for junior doctors and pharmacists
Disorders of the respiratory system 2
BVCOG HRSA/HAB Tier 2 and 3 Performance Measures Lisa Cornelius, MD, MPH July 2010.
COPD Research at the University of Maryland School of Maryland COPD Clinical Research Center A member of the National Heart Lung & Blood Institute National.
Pneumonia Why do we need to know about it? Long recognized as a major cause of death, Pneumonia has been studied intensively since late 1800s. Despite.
Pneumonia: nursing management Islamic University Nursing College.
Community- acquired Pneumonia Author Dr. Shek Kam Chuen Oct 2013 HKCEM College Tutorial.
Professor of Respiratory Medicine
PHL 424 Antimicrobials 9 th Lecture By Abdelkader Ashour, Ph.D. Phone:
Resident Report Bronchiectasis Irreversibly dilated peripheral airways secondary to chronic inflammation from a variety of causes Pathogenesis.
Drugs For Treating Asthma
Management of Patients With Chronic Pulmonary Disease.
Faculty Research Advisor: Dr. David Blake. Background Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide and.
Pathology of chronic obstructive airway diseases
Brittany Skaehill, Julian Rulan, Maryna Ugalde, & Katlyn Feick.
Rapivab™ - peramivir injection
Habib GHEDIRA, MD, Prof. Medical Faculty of Tunis
سورة البقرة ( ۳۲ ). Influenza is a serious respiratory illness which can be debilitating and causes complications that lead to hospitalization and.
AMINOGLYCOSIDES The different members of this group share many properties in common. The different members of this group share many properties in common.
Bronchitis Causes Bronchitis occurs most often during the cold and flu season, usually coupled with an upper respiratory infection. A number of bacteria.
Respiratory Tract infections. PROF. AzzA ELMedany Department of pharmacology.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 9 Tetracyclines, Macrolides, and Lincosamides.
Chemotherapy of Tuberculosis By Prof. Azza El-Medany.
ANTIVIRAL AGENTS FOR THE PREVENTION AND TREATMENT ON INFLUENZA.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
Respiration & Health. Upper Respiratory Infections  URI: Common  Warm mucus + moist + Germs in air = killer sneeze and/or cough.
Advanced Asthma Training Course Mechanisms Of Asthma Part II Dr.Hadeel A.K AlOtair ABIM,MRCP(UK),FCCP Assisstant professor of Medicine consultant pulmonologist.
Chronic Obstructive Pulmonary Disease Austin Paul K.
Antimicrobial drugs. Antimicrobial drugs are effective in the treatment of infections because of their selective toxicity (that is, they have the ability.
Angelo L Gaffo Kenneth G Saag Core Evidence 2009:4 25–36
Exacerbations. Exacerbations An exacerbation of COPD is an acute event characterized by a worsening of the patient’s respiratory symptoms that is beyond.
Presented by: Bobbie Jo Bennett, Kristen Franklin, & Lacey McGallion
Disorders of the Respiratory System PAGES
Disorders of the respiratory system 2. Bronchitis is an obstructive respiratory disease that may occur in both acute and chronic forms. Acute bronchitis:
Treatment of Infectious Diseases. ›Drugs used to treat bacterial diseases are grouped into categories based on their modes of action Treatment of Bacterial.
Management of Patients With Chronic Pulmonary Disease
Respiratory System Disorders. Diseases and Infections interfere in two main ways: 1)Restrict the flow of air into and out of the lungs 2)Impairs the.
Treatment Of Respiratory Tract infections. Prof. Azza ELMedany Department of Pharmacology Ext
* QUINIDINE  Quinidine has pronounced cardiac anti muscarinic effects. It is absorbed orally. It undergoes extensive metabolism by the hepatic cytochrome.
Management Of Exacerbations Of Chronic Obstructive Pulmonary Disease D.Anan Esmail Seminar Training Primary Care Asthma + COPD
September 16, 2014 Bedford Senior Center Joyce Cheng RN Community Health Nurse Bedford Board of Health.
COPD? Where Are We Headed?
Daniel B. Jamieson, Elizabeth C. Matsui, Andrew Belli1, Meredith C. McCormack, Eric Peng Simon Pierre-Louis, Jean Curtin-Brosnan, Patrick N. Breysse, Gregory.
폐렴으로 오인할 수 있는 폐렴 외 질환 호흡기 내과 R3 최 문 찬.
Hot Topics in Antibiotic Management of Pediatric CF Lung Disease Mike Tracy, MD Fellow, Pediatric Pulmonary.
Management Of Exacerbations Of Chronic Obstructive Pulmonary Disease D.Anan Esmail Seminar Training Primary Care Asthma + COPD
Management of stable chronic obstructive pulmonary disease (2) Seminar Training Primary Care Asthma + COPD D.Anan Esmail.
Treatment of Respiratory Tract infections. Prof. Azza EL-Medany.
Azithromycin – for better or worse in chronic lung infection? Professor Emma Baker Professor of Clinical Pharmacology St George's, University of London.
Antibiotics in Addition to Systemic Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease Johannes M.A. Daniels; Dominic snijders;
CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.
< review conference>
Protein Synthesis Inhibitors
Addition of Inhaled Tobramycin to Ciprofloxacin for Acute Exacerbations of Pseudomonas aeruginosa Infection in Adult Bronchiectasis* Diana Bilton, MD;
Miguel Angel Martı´nez-Garcı´a, MD; Juan-Jose Soler-Catalun˜ a, MD;
Treatment of Infectious Diseases
PHARMACOTHERAPY III PHCY 510
CAP Therapy Babak Sayad Associate Professor of Infectious Diseases
COPD Exacerbations UCI Internal Medicine Mini-Lecture
Other Protein Synthesis Inhibitor
بنام خداوند جان و خرد بنام خداوند جان و خرد.
COPD Exacerbation (1) C.L.I.P.S.
Investigate the Treatment of Infectious Diseases
Presentation transcript:

1 Antibiotic Prevention of Acute Exacerbations of COPD Dr Farhad Abbasi Infectious Diseases Specialist

2 Globally, COPD is the fourth leading cause of death. An estimated 24 million persons in the United States have COPD on the basis of lung-function testing.

The average person with COPD has one to two acute exacerbations each year, with wide variation from patient to patient. 3

During an acute exacerbation, antibiotics are generally administered for 5 to 10 days, creating a national burden of 120 million to 480 million antibiotic-days annually. 4

The median hospital stay per exacerbation has been estimated at 9 days Acute exacerbations also accelerate the progressive decline in lung function associated with COPD. 5

COPD is characterized by chronic airway inflammation resulting in increased mucus production and airway ciliary malfunction. The inflammatory process leads to destruction of respiratory bronchioles, parenchymal loss, and thickening of the vascular wall 6

Exacerbations of COPD have been shown to coincide with acute respiratory viral infections. picornaviruses, influenza virus, and respiratory syncytial virus 7

At the same time, the sputum of patients with COPD is colonized with bacteria, often with newly acquired strains of known pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. 8

Members of the macrolide class of antibiotics including erythromycin, clarithromycin, and azithromycin inhibit bacterial RNA-directed protein assembly by binding to the 50S subunit of bacterial ribosomes. 9

In addition to their antimicrobial efficacy, macrolides have been shown to have antiinflammatory and immune-modulating effects 10

A recent large clinical trial involving 1142 volunteers examined the hypothesis that daily administration of 250 mg of azithromycin for 1 year would reduce the frequency of acute exacerbations of COPD. 11

In another long-term, placebo-controlled clinical trial examining macrolide antibiotics in the prevention of acute exacerbations of COPD involving 109 patients, erythromycin was the active drug, given at a dose of 250 mg twice daily for 1 year. 12

COPD management Smoking cessation Enrollment in a pulmonary rehabilitation program Use of evidence-based medications, including: 1. long-acting inhaled beta-agonists 2. long-acting inhaled anticholinergic agents 3. inhaled glucocorticoids 13

A patient who continues to have frequent acute exacerbations despite guidelines- based treatment is a potential candidate for prophylactic use of azithromycin 14

azithromycin is an inhibitor of the cytochrome P-450 enzyme CYP3A4, it should not be used if the patient is taking any drug that is metabolized by that enzyme. 15

Dose adjustment is not needed for renal dysfunction. However, because macrolides are metabolized in the liver, we suggest not using azithromycin if the patient has moderate or severe liver disease, as indicated by serum aminotransferase levels of more than three times the upper limit of the normal range. 16

we suggest follow-up evaluations every 3 months, at which time all the initial screening, including audiography and electrocardiography, should be repeated. The physician should ask the patient about hearing problems, disequilibrium, and tinnitus, which might be signs of ototoxicity. 17

since any antibiotic can select for Clostridium difficile, the patient should be asked about diarrhea and other gastrointestinal symptoms. 18

Adverse Effects Ototoxicity Cardiac toxicity Drug–drug interactions. 19

Hearing loss, disequilibrium, and tinnitus are potential adverse effects of macrolides 20

Macrolide antibiotics prolong the QTc interval by blocking a cardiac potassium channel A prolonged QTc interval is associated with an increased risk of torsades de pointes, potentially resulting in ventricular fibrillation and sudden death. 21

we suggest avoiding the use of azithromycin in patients with a high risk of baseline cardiovascular disease. Such patients include those with congestive heart failure, cerebrovascular disease, and peripheral vascular disease 22

Macrolides also inhibit the CYP3A4 isoenzyme, thus increasing serum levels of other drugs metabolized by this enzyme 1. Statins 2. Warfarin 3. amiodarone 23

Long-term macrolide prophylaxis Ddiffuse panbronchiolitis Cystic fibrosis Bronchiectasis Prevention of Mycobacterium avium complex infection in patients with the AIDS and a CD4+ <50 cells per cubic millimeter 24

Some experts are promoting the idea of screening patients with COPD for colonization with nontuberculous mycobacteria and withholding macrolide prophylaxis in those with positive sputum cultures 25

would suggest discontinuing the drug if important adverse effects surface or if the number of exacerbations does not decrease during the first year of treatment. 26

Qquinolones should not be preferred over macrolides for COPD prophylaxis, because they are so important for treating community- acquired pneumonia. 27

28

29